IL2RA and chronic myelogenous leukemia, BCR-ABL1 positive: This shows the major interest of targeted therapy via CD25 CAR-NK92 cells against K562 cells expressing CD25, validating the potential of this strategy for future clinical use in blast-phase CML and AML.